Drug intelligence / Profile preview

TQA3729

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQA3729 is an orally bioavailable small molecule agonist of Toll-like receptor 8 (TLR8) developed by Jiangsu Chia Tai Tianqing Pharmaceutical for the treatment of chronic hepatitis B (CHB). By selectively activating TLR8, the drug induces the production of endogenous cytokines such as IL-12 and TNF-α from myeloid cells, which in turn stimulates innate and adaptive immune responses to promote the clearance of HBV-infected cells. It is currently being investigated in Phase 2 clinical trials as a potential component of a functional cure regimen for patients with CHB.

Targets

TLR8 (Toll-like receptor 8)

Beyond the preview

Go deeper on TQA3729.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQA3729.

Explore the full profile